77 related articles for article (PubMed ID: 27818289)
1. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
2. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
3. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract][Full Text] [Related]
4. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.
Tang H; Liu Y; Wang X; Guan L; Chen W; Jiang H; Lu Y
Medicine (Baltimore); 2018 May; 97(21):e10881. PubMed ID: 29794794
[TBL] [Abstract][Full Text] [Related]
5. Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer.
Cantón-Romero JC; Miranda-Díaz AG; Bañuelos-Ramírez JL; Carrillo-Ibarra S; Sifuentes-Franco S; Castellanos-González JA; Rodríguez-Carrizalez AD
Oxid Med Cell Longev; 2017; 2017():2873030. PubMed ID: 28848618
[TBL] [Abstract][Full Text] [Related]
6. ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer.
Hua T; Wang RM; Zhang XC; Zhao BB; Fan SB; Liu DX; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34793589
[TBL] [Abstract][Full Text] [Related]
7. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Funingana IG; Reinius MAV; Petrillo A; Ang JE; Brenton JD
Semin Cancer Biol; 2021 Dec; 77():67-82. PubMed ID: 33607245
[TBL] [Abstract][Full Text] [Related]
8. Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.
O'Connor JP; Jayson GC; Jackson A; Ghiorghiu D; Carrington BM; Rose CJ; Mills SJ; Swindell R; Roberts C; Mitchell CL; Parker GJ
Clin Cancer Res; 2007 Oct; 13(20):6130-5. PubMed ID: 17947478
[TBL] [Abstract][Full Text] [Related]
9. Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.
Khan MA; Vikramdeo KS; Sudan SK; Singh S; Wilhite A; Dasgupta S; Rocconi RP; Singh AP
Semin Cancer Biol; 2021 Dec; 77():99-109. PubMed ID: 34418576
[TBL] [Abstract][Full Text] [Related]
10. Related clinical factors of platinum-based chemotherapy resistance in patients with epithelial ovarian cancer.
Xiong Z; Ha C; Li R; Wu M; Wei M
Gynecol Obstet Invest; 2024 Jun; ():. PubMed ID: 38824927
[TBL] [Abstract][Full Text] [Related]
11. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ghoneum A; Almousa S; Warren B; Abdulfattah AY; Shu J; Abouelfadl H; Gonzalez D; Livingston C; Said N
Semin Cancer Biol; 2021 Dec; 77():83-98. PubMed ID: 33476723
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma.
Luk HM; Wang DY; Xie LL; Liu XY; Xu GC; Lu HW
Int J Clin Exp Pathol; 2020; 13(5):1197-1205. PubMed ID: 32509095
[TBL] [Abstract][Full Text] [Related]
13. Role of Serine arginine protein kinase 1 and Minichromosome maintenance protein 2 in predicting epithelial ovarian cancer response to treatment and prognosis.
Elkholy E; Abdou AG; Alhanafy AM; Hashem T; Hassan R; Shehata M
Indian J Cancer; 2024 Jan; ():. PubMed ID: 38216547
[TBL] [Abstract][Full Text] [Related]
14. CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance.
Sapoznik S; Aviel-Ronen S; Bahar-Shany K; Zadok O; Levanon K
Oncotarget; 2017 Sep; 8(37):62240-62247. PubMed ID: 28977941
[TBL] [Abstract][Full Text] [Related]
15. Predicting platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
Amjad M
BJOG; 2024 Feb; ():. PubMed ID: 38351671
[No Abstract] [Full Text] [Related]
16. Expression of HPIP in epithelial ovarian carcinoma: a clinicopathological study.
Wang Y; Meng F; Liu Y; Chen X
Onco Targets Ther; 2017; 10():95-100. PubMed ID: 28053543
[TBL] [Abstract][Full Text] [Related]
17. CSR1 suppresses tumor growth and metastasis of human hepatocellular carcinoma via inhibition of HPIP.
Jiang L; Hu G; Chen FF; Du XY; Liu B; Liu C
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3813-3820. PubMed ID: 28975986
[TBL] [Abstract][Full Text] [Related]
18. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
19. Two decades of a protooncogene HPIP/PBXIP1: Uncovering the tale from germ cell to cancer.
Khumukcham SS; Manavathi B
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188576. PubMed ID: 34090932
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic PBX-interacting protein mediates cartilage degeneration during the pathogenesis of osteoarthritis.
Ji Q; Xu X; Kang L; Xu Y; Xiao J; Goodman SB; Zhu X; Li W; Liu J; Gao X; Yan Z; Zheng Y; Wang Z; Maloney WJ; Ye Q; Wang Y
Nat Commun; 2019 Jan; 10(1):313. PubMed ID: 30659184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
